ACHV - Achieve Life Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4500
+0.0300 (+2.11%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.4200
Open1.4100
Bid1.32 x 1000
Ask1.46 x 1000
Day's Range1.3601 - 1.4500
52 Week Range1.3200 - 32.0000
Volume61,604
Avg. Volume1,117,693
Market Cap9.746M
Beta (3Y Monthly)3.34
PE Ratio (TTM)N/A
EPS (TTM)-5.99
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
    Zacks18 days ago

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

  • 5 Top-Ranked Rising P/E Stocks to Lure Investors
    Zacks19 days ago

    5 Top-Ranked Rising P/E Stocks to Lure Investors

    Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

  • Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
    PR Newswirelast month

    Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update

    SEATTLE and VANCOUVER, British Columbia , Nov. 7, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
    PR Newswire2 months ago

    Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018

    SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 31, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline (cytisine) for smoking cessation, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update.

  • ACCESSWIRE2 months ago

    3 Healthcare Stocks that Could Move on Industry Growth

    CORAL GABLES, FL / ACCESSWIRE / October 30, 2018 / According to the MarketsAndMarkets* report "Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021", the market for healthcare IT is expected to reach $280.25 Billion by 2021 at a CAGR of 15.9% during the forecast period. HealthVue is a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients.

  • Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation
    PR Newswire2 months ago

    Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation

    SEATTLE and VANCOUVER, British Columbia, Oct. 30, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced initiation of the Phase 2b ORCA-1 trial for smoking cessation. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, that aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other indications. This Phase 2b trial will evaluate both the 1.5mg and 3mg doses of cytisinicline on a declining titration schedule over 25 days, as well as three times daily dosing.

  • InvestorPlace2 months ago

    Achieve Life Sciences Stock Will Probably Tumble Further

    After an impressive 48.8% gain last week by Achieve Life Sciences (NASDAQ:ACHV) stock, ACHV stock has given up nearly all of its gains this week. ACHV stock price jumped on Sept. 27 after the company reported the results of a clinical study, but the shares went on to lose practically all of their gains by Oct. 1. ACHV stated that a new formulation of its  smoking cessation aid – cytisine – showed similar bioavailability when the subjects were fed and when they fasted.

  • Achieve Announces Pricing of $5.6 Million Registered Direct Offering
    PR Newswire3 months ago

    Achieve Announces Pricing of $5.6 Million Registered Direct Offering

    SEATTLE and VANCOUVER, British Columbia, Oct. 1, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,789,258 shares of common stock at a price of $3.1445 per share in a registered direct offering, resulting in total gross proceeds of approximately $5.6 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to 0.5 share of common stock for each share purchased with an exercise price of $3.1445 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American: LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

  • MarketWatch3 months ago

    Achieve Life Sciences' stock rockets on positive study results for smoking cessation drug

    Shares of Achieve Life Sciences Inc. shot up 31% to pace all premarket gainers Thursday, after the clinical-stage pharmaceutical company announced positive results from a study of its smoking cessation drug. Volume of 509,000 shares ahead of the open was already more than five times the full-day average. The company said the study evaluated the bioavailability of a new formulation of 3 milligram cytisine under fed and fasted conditions. "Study results demonstrated bioequivalence when cytisine was administered with or without food," the company said in a statement. "Cytisine was extensively absorbed after oral administration with maximum cytisine concentration levels observed in the blood within less than two hours with or without food." The stock has tumbled 33% over the past three months, while the S&P 500 has gained 7.6%.

  • Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects
    PR Newswire3 months ago

    Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects

    SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine. The study evaluated the bioavailability of a new formulation of 3 mg cytisine under fed and fasted conditions in 12 healthy volunteer smokers.

  • Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018
    PR Newswire3 months ago

    Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018

    SEATTLE and VANCOUVER, British Columbia , Sept. 26, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy
    PR Newswire3 months ago

    Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy

    The observational study compared the effectiveness of cytisine and nicotine replacement therapy (NRT) as an aid to smoking cessation in the Russian Federation. Evaluation of 301 subjects who had used either cytisine or NRT determined that smokers in the cytisine group were approximately three times more likely to achieve 90-days abstinence compared to those who attempted to quit with NRT (p=0.011).

  • Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference
    PR Newswire3 months ago

    Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference

    The presentations include a review of cytisine's safety profile and an overview of Achieve's upcoming Phase 2b study, planned to initiate later this year. "This conference provides an excellent opportunity to update the scientific community on the progress we continue to make in advancing the global availability of cytisine," commented Dr. Cindy Jacobs, MD, PhD, Chief Medical Officer of Achieve. Two, investigator-sponsored Phase 3 clinical trials of cytisine were successfully completed in over 2,000 patients.

  • Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018
    PR Newswire3 months ago

    Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018

    SEATTLE and VANCOUVER, British Columbia , Sept. 5, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • PR Newswire4 months ago

    Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update

    SEATTLE and VANCOUVER, British Columbia , Aug. 8, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • PR Newswire5 months ago

    Achieve Life Sciences to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 8, 2018

    SEATTLE and VANCOUVER, British Columbia, Aug. 2, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it will report its second quarter 2018 financial results on Wednesday, August 8, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: Achieve Life Sciences and Pfizer

    NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Shares of Achieve Life Sciences exploded on Wednesday after the company announced the advancement of the Cytisine Development Program after its meeting with ...

  • Benzinga5 months ago

    Achieve Life Sciences Shares Surge On Development Plan For Smoking Cessation Candidate

    Achieve Life Sciences Inc (NASDAQ: ACHV) shares are skyrocketing as the clinical-stage biotech moves one step closer to filing a New Drug Application for its smoking cessation pipeline candidate cytisine. The company said it will conduct a Phase 2b optimization trial in about 250 smokers in the U.S., with various dosing schedules to determine efficacy, safety and compliance profiles.

  • PR Newswire5 months ago

    Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA

    SEATTLE and VANCOUVER, British Columbia, July 11, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States (U.S.) Food and Drug Administration (FDA). The meeting with the FDA on the non-clinical and clinical development plans has further defined Achieve's Phase 3 clinical program and expected future New Drug Application (NDA) submission. Based on the FDA's recommendations to further characterize cytisine dosing prior to NDA submission, Achieve plans to conduct a Phase 2b optimization trial in approximately 250 smokers in the U.S., with various cytisine dosing schedules to evaluate overall treatment efficacy, safety, and compliance profiles for cytisine.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Puma Biotechnology and Achieve Life Sciences

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Biotech stocks Puma Biotechnology and Achieve Life Sciences soared in Tuesday's trading session after each company had positive developments. Puma rose after ...

  • Benzinga6 months ago

    Achieve Life Sciences Shares Rip Higher On Positive Data For Smoking Cessation Drug

    Achieve Life Sciences Inc (NASDAQ: ACHV ) shares were posting double-digit gains Tuesday on roughly 83 times the stock's average volume. The stock was up 31 percent at the time of publication at $4.97. ...

  • PR Newswire6 months ago

    Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction

    The study demonstrated that cytisine has no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters. This suggests that cytisine may be administered with other medications without the need to modify the dose of the co-administered drug. Dr. Anthony Clarke, Chief Scientific Officer of Achieve commented: "We are very pleased with the results of these detailed studies.

  • PR Newswire6 months ago

    Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    SEATTLE and VANCOUVER, British Columbia, June 19, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering was comprised of Class A Units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.

  • PR Newswire6 months ago

    Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering

    SEATTLE and VANCOUVER, British Columbia, June 15, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is comprised of Class A units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.

  • PR Newswire6 months ago

    Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules

    The University of Bristol strategic collaboration uses a combination of computational docking and chemical synthesis to design and generate precision chemical keys for important biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine-mediated neurotransmission have been linked to several neurological conditions and public health issues, notably tobacco addiction.